Curis $CRIS licensed their hedgehog inhibitor ERIVEDGE (vismodegib) to Roche. There was no mention of the drug on the 2q-2012 quarterly conference call. Sales have totaled about $10m since launch in early 2012 for advanced basal cell carcinoma (BCC), generating ~$0.5m in royalties to Curis. The earnings press release had the following update:
"Erivedge became the first and only FDA-approved treatment for advanced forms of basal cell carcinoma in February this year. It is also the first in a new class of anti-cancer treatments called hedgehog pathway inhibitors.Early market response is encouraging. Roche has submitted Erivedge for marketing approval in the EU, Australia, Mexico, Israel and Canada."
Approval in Europe is forecast to occur in 2h-2012 or early in 2013.
If interested, the drug was of course discussed in much greater detail on the CRIS quarterly call, including comments on sales growth, market dynamics, ongoing clinical trials, etc. Check it out on EarningsCast if interested.
"Erivedge became the first and only FDA-approved treatment for advanced forms of basal cell carcinoma in February this year. It is also the first in a new class of anti-cancer treatments called hedgehog pathway inhibitors.Early market response is encouraging. Roche has submitted Erivedge for marketing approval in the EU, Australia, Mexico, Israel and Canada."
Approval in Europe is forecast to occur in 2h-2012 or early in 2013.
If interested, the drug was of course discussed in much greater detail on the CRIS quarterly call, including comments on sales growth, market dynamics, ongoing clinical trials, etc. Check it out on EarningsCast if interested.
RSS Feed
